AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Ion Beam Applications, SA

Declaration of Voting Results & Voting Rights Announcements Dec 17, 2012

3960_mrq_2012-12-17_0547621d-631b-472a-a322-7796ac758247.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Press release |

Regulatory information

IBA – DATA CONCERNING TRANSPARENCY

For immediate publication – 17 December 2012

Louvain-la-Neuve, Belgium, 17 December 2012 - IBA (Ion Beam Applications SA) communicates today the basic and additional data as per Article 15 §1 al.1 of the Transparency Law, following its capital increase dated 17 December 2012.

Data concerning transparency Heading II of the law of May 2, 2007 and the Royal Decree of February 14, 2008

Communication of the basic data as per Article 15 §1 al.1 of the Law


Total capital:
Total number of securities conferring the voting right:
12 639 438 with VVPR strips)
EUR 38 420 256.59
27 374 028 (of which
Total number of voting rights (= the denominator): 27 374 028
Total number of securities conferring the voting right, by category: N/A
Total number of voting rights, by category: N/A
Communication of the additional data as per Article 15 §1 al.2 of the Law

Total number of convertible bonds conferring the voting right:
Total number of rights, materialized or not by certificates, giving the
right to subscribe to newly issued securities conferring the voting right
0
(e.g. warrants): 2 735 433
Total number of voting rights which would result from the exercise of
these conversion or subscription rights: 2 735 433
Total number of shares without voting right: 0

Statutory thresholds as per Article 18 of the Law

The applicable thresholds as follows: three percent, five percent, ten percent, fifteen percent and so on by brackets of five percent.

Contact person IBA Xavier Defourt, Chief Legal Officer +32 10 48 77 82 [email protected].

ABOUT IBA

Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the medical industry. It develops and markets state-of-the-art equipment and radiopharmaceuticals for cancer diagnosis and treatment. In addition, it uses the scientific expertise thus gained to provide electron accelerators for industrial sterilization and ionization. Listed on the pan-European stock exchange Euronext, IBA is included in the BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Website: http://www.iba-worldwide.com

Press release | 17 December 2012 1 | 1

Talk to a Data Expert

Have a question? We'll get back to you promptly.